CING Stock Price, Cingulate Inc. Quote, Chart

Market Summary

USD0.80+0.01

Delayed

1.27%

CING Stock Price

View Fullscreen

CING RSI Chart

CING Valuation

Market Cap

4.8M

Price/Earnings (Trailing)

-0.21

EV/EBITDA

-0.17

Price/Free Cashflow

-0.24

MarketCap/EBT

-0.21

CING Price/Earnings (Trailing)

CING Profitability

Return on Equity

-699.68%

Return on Assets

-409.55%

Free Cashflow Yield

-423.24%

CING Fundamentals

CING Earnings

Earnings (TTM)

-22.5M

Earnings Growth (Yr)

25.78%

Earnings Growth (Qtr)

57.14%

Breaking Down CING Revenue

Last 7 days

5.3%

Last 30 days

-5.9%

Last 90 days

-31.0%

Trailing 12 Months

-95.9%

How does CING drawdown profile look like?

CING Financial Health

Current Ratio

1.21

CING Investor Care

Buy Backs (1Y)

48.34%

Diluted EPS (TTM)

-14.75

Tracking the Latest Insider Buys and Sells of Cingulate Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 11, 2024	werth peter j.	acquired	753	0.000727054	1,036,010	-
Sep 15, 2023	callahan jennifer l.	bought	3,348	0.6697	5,000	corporate controller
Aug 11, 2023	werth peter j.	bought	1,000,000	0.5485	1,823,160	-
May 15, 2023	callahan jennifer l.	bought	2,020	1.01	2,000	corporate controller
May 12, 2023	callahan jennifer l.	bought	4,320	1.08	4,000	corporate controller
Dec 16, 2022	schaffer shane j.	bought	10,166	1.0166	10,000	chief executive officer
Dec 14, 2022	callahan jennifer l.	bought	7,467	0.9894	7,548	corporate controller
Dec 14, 2022	schaffer shane j.	bought	13,399	1.01	13,267	chief executive officer
Dec 13, 2022	werth peter j.	bought	28,421	0.9823	28,934	-
Dec 13, 2022	schaffer shane j.	bought	1,750	1.01	1,733	chief executive officer

Which funds bought or sold CING recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	BANK OF AMERICA CORP /DE/	unchanged	-	-3.00	3.00	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	reduced	-6.23	-17,314	2,698	-%
May 15, 2024	Altium Capital Management LP	unchanged	-	-2,403	5,697	-%
May 15, 2024	ARMISTICE CAPITAL, LLC	reduced	-95.00	-182	433	-%
May 15, 2024	SABBY MANAGEMENT, LLC	reduced	-16.18	-9,698,000	7,078,000	-%
May 15, 2024	Tower Research Capital LLC (TRC)	added	896	2,688	8,892	-%
May 15, 2024	Hudson Bay Capital Management LP	unchanged	-	-1,792	4,532	-%
May 14, 2024	Qube Research & Technologies Ltd	new	-	110	110	-%
May 13, 2024	HRT FINANCIAL LP	new	-	11,000	11,000	-%
May 13, 2024	UBS Group AG	reduced	-99.82	-1,424	1.00	-%

Are Funds Buying or Selling CING?

Are funds buying CING calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CING

No. of Funds

Unveiling Cingulate Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 12, 2024	werth peter j.	19.48%	1,178,108	SC 13D/A
Feb 28, 2024	werth peter j.	19.95%	1,171,055	SC 13D/A
Feb 09, 2024	lind global fund ii lp	9.9%	282,000	SC 13G
Feb 09, 2024	werth peter j.	19.99%	958,440	SC 13D/A
Jan 29, 2024	werth peter j.	19.99%	327,085	SC 13D/A
Jan 04, 2024	schaffer shane j.	3.65%	53,305	SC 13D/A
Jan 04, 2024	werth peter j.	19.99%	327,085	SC 13D/A
Nov 08, 2023	werth peter j.	19.99%	3,977,472	SC 13D/A
Sep 18, 2023	werth peter j.	19.9%	2,839,715	SC 13D/A
Sep 18, 2023	schaffer shane j.	5.7%	990,300	SC 13D/A

Recent SEC filings of Cingulate Inc.

View All Filings

Date Filed	Form Type	Document
May 17, 2024	S-1	Initial Public Offering
May 13, 2024	8-K	Current Report
May 08, 2024	10-Q	Quarterly Report
May 08, 2024	8-K	Current Report
Apr 26, 2024	ARS	ARS
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	DEFA14A	DEFA14A
Apr 12, 2024	SC 13D/A	13D - Major Acquisition
Apr 12, 2024	4	Insider Trading
Apr 04, 2024	S-8	Employee Benefits Plan

Peers (Alternatives to Cingulate Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Cingulate Inc. News

Latest updates

Cingulate Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet											(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2020Q4
Assets	57.4%	5,495	3,491	5,870	5,227	7,163	11,405	15,377	13,804	18,433	22,886	5,788
Current Assets	371.3%	2,727	579	2,902	2,038	3,753	7,870	11,834	10,102	14,574	18,882	1,790
Cash Equivalents	2025.0%	1,114	52.00	1,986	350	1,739	5,356	9,796	8,196	12,614	16,493	1,198
Net PPE	-3.2%	2,464	2,546	2,531	2,686	2,841	2,905	2,851	2,953	3,054	3,145	3,039
Liabilities	-78.0%	2,278	10,361	5,967	11,326	7,081	7,523	7,010	1,619	2,414	2,043	4,495
Current Liabilities	-78.0%	2,245	10,226	5,732	10,995	6,659	7,013	6,406	924	1,631	1,177	3,361
Shareholder's Equity	146.8%	3,216	-6,869	-	-	82.00	3,882	8,367	12,185	16,019	20,844	1,292
Retained Earnings	-3.2%	-95,915	-92,943	-86,008	-80,029	-73,413	-69,408	-64,803	-60,776	-56,735	-51,732	-31,022
Additional Paid-In Capital	15.2%	99,132	86,074	85,912	73,930	73,494	73,290	73,169	72,963	72,756	72,576	-
Shares Outstanding	329.2%	5,010	1,168	-	12,057	11,309	-	-	11,309	11,309	-	-
Float	-	-	-	-	7,800	-	-	-	11,500	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)														(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Cashflow From Operations	-241.3%	-8,746	-2,562	-4,291	-4,603	-3,576	-4,206	-3,399	-4,412	-3,864	-4,622	-2,585	-1,550	-1,674	-
Share Based Compensation	6.5%	165	155	236	217	204	206	206	207	182	-	-	-	-	-
Cashflow From Investing	56.4%	-81.51	-186	-	-1*	-37.13	-143	3.00	-2.48	-10.40	-710	-15.77	-22.49	-66.47	-
Cashflow From Financing	1112.8%	9,889	815	5,928	3,215	-3.92	-89.78	4,996	-3.74	-3.68	19,910	3,472	1,809	1,351	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

CING Income Statement

2024-03-31

Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 1,806,985	$ 2,128,616
General and administrative	1,141,232	1,721,379
Operating loss	(2,948,217)	(3,849,995)
Interest and other income (expense), net	(24,260)	(154,892)
Loss before income taxes	(2,972,477)	(4,004,887)
Income tax benefit (expense)
Net loss and comprehensive loss	$ (2,972,477)	$ (4,004,887)
Net loss per share of common stock, basic	$ (0.60)	$ (7.08)
Net loss per share of common stock, diluted	$ (0.60)	$ (7.08)
Weighted average number of shares used in computing net loss per share of common stock, basic	4,945,507	565,471
Weighted average number of shares used in computing net loss per share of common stock, diluted	4,945,507	565,471

CING Balance Sheet

2024-03-31

Consolidated Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 1,113,830	$ 52,416
Miscellaneous receivables	2,247	14,622
Prepaid expenses and other current assets	1,610,765	511,556
Total current assets	2,726,842	578,594
Property and equipment, net	2,463,874	2,545,965
Operating lease right-of-use assets	303,799	366,877
Total assets	5,494,515	3,491,436
Current liabilities:
Accounts payable	737,949	5,199,105
Accrued expenses	1,117,638	1,651,519
Note payable		3,000,000
Finance lease liability, current	17,326	17,057
Operating lease liability, current	372,338	358,085
Total current liabilities	2,245,251	10,225,766
Long-term liabilities:
Finance lease liability, net of current		4,436
Operating lease liability, net of current	33,145	130,663
Total long-term liabilities	33,145	135,099
Total liabilities	2,278,396	10,360,865
Stockholders’ Equity
Common Stock, $0.0001 par value; 240,000,000 shares authorized and 5,010,470 and 1,167,521 shares issued and outstanding as of March 31, 2024 and December 31, 2023	502	118
Preferred Stock, $0.0001 par value; 10,000,000 shares authorized and 0 shares issued and outstanding as of March 31, 2024 and December 31, 20223
Additional Paid-in-Capital	99,131,537	86,073,896
Accumulated deficit	(95,915,920)	(92,943,443)
Total stockholders’ equity	3,216,119	(6,869,429)
Total liabilities and stockholders’ equity	$ 5,494,515	$ 3,491,436

About Cingulate Inc.

Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders intended for children, adolescents, and adults. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

CEO	Dr. Shane J. Schaffer Pharm.D., PharmD
WEBSITE	cingulate.com
INDUSTRY	Biotechnology
EMPLOYEES	15

Cingulate Inc. Frequently Asked Questions

What is the ticker symbol for Cingulate Inc.? What does CING stand for in stocks?

CING is the stock ticker symbol of Cingulate Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Cingulate Inc. (CING)?

As of Fri May 17 2024, market cap of Cingulate Inc. is 4.84 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CING stock?

You can check CING's fair value in chart for subscribers.

What is the fair value of CING stock?

You can check CING's fair value in chart for subscribers. The fair value of Cingulate Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Cingulate Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CING so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Cingulate Inc. a good stock to buy?

The fair value guage provides a quick view whether CING is over valued or under valued. Whether Cingulate Inc. is cheap or expensive depends on the assumptions which impact Cingulate Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CING.